Analysts: Incyte Share Valuation Is Rich and 3 More Research Notes to Browse Through

Incyte (NASDAQ:INCY): Goldman says that Incyte’s Jakafi data in pancreatic cancer is encouraging but share valuation is rich. The firm believes the Street is assigning other solid cancers values to Jakafi, which it views as premature, and notes limited subgroup criteria visibility. Shares are Sell rated with a $26 price target, raised from $17.

incy-20130822

Diamond Foods (NASDAQ:DMND): DA Davidson has increased its target to $24 from $20 on Diamond Foods after the company announced the terms of its preliminary settlement, subject to court approval, of the private securities class action pending against it. The firm notes that the company also pre-announced better-than-expected fourth-quarter results, but it reiterates a Neutral rating on the stock.

dmnd-20130822

Green Mountain Coffee (NASDAQ:GMCR):  Dougherty says that K-Cup IRI Data year over year for the fuor-week period that ended August 8 was 24.5 percent, down from a previous 30.2 percent.

gmcr-20130822

Outerwall (NASDAQ:OUTR): ITG Research believes that Redbox’s third-quarter DVD rental revenue is tracking to $515 million-$525 million, below the consensus of $529 million.

outr-20130822

Investing Insights: Can Johnson & Johnson Continue This Bull Run?